Search for IGF-1 LR3 before and after and you will find transformation galleries, cycle logs, and confident milligram numbers. What you will not find, anywhere in the published literature, is a single human study of the compound in those photos.
That is the whole problem in one sentence. IGF-1 LR3 has a real biochemistry and a genuine scientific pedigree, but the pedigree belongs to a laboratory reagent and the human clinical record belongs to a different molecule entirely.
What IGF-1 LR3 is, and what it was built for
Long R3 IGF-1 is not insulin-like growth factor 1. It is an engineered variant of it, carrying a glutamate-to-arginine substitution at position 3 and a hydrophobic 13-amino-acid extension bolted onto the N-terminus.[1] Two deliberate edits to a natural hormone.
The point of edits like these was never physique enhancement. Researchers used site-directed mutagenesis on IGF-1 specifically to map which parts of the molecule bind the receptor and which parts bind the binding proteins, and then to build analogues with selective affinity for one and not the other.[2] Long R3 is a product of that programme: a molecule tuned to slip past the proteins that would normally hold it.
Read the papers that mention it by name and you find studies of refolding pathways and pepsin resistance. This is the literature of a reagent being characterised, not a therapy being tested.
The human evidence is for a different molecule
Everything people cite as “IGF-1 works” comes from research on recombinant human IGF-1, which is plain IGF-1, not the Long R3 variant.
That research is real but narrow. Severe primary IGF-1 deficiency is a defined clinical condition: a child with very low circulating IGF-1 and severe short stature, despite normal or elevated growth hormone, and it is managed with recombinant human IGF-1.[3] Children with the condition have been treated and followed for years, in cohorts numbering in the dozens.[4]
Dozens. That is the scale of the population in which this hormone has a settled therapeutic role.
Outside that indication, recombinant IGF-1 has been pushed into places far from short stature, including a randomised phase 2b trial in preterm infants with bronchopulmonary dysplasia.[5] Notice what is absent from that list of investigated uses: healthy adults who want more muscle. Nobody has run that trial. Not for IGF-1, and certainly not for Long R3.
How IGF-1 drives muscle growth
The mechanism is not in doubt, and this is precisely why the compound is persuasive.
Signalling through the type 1 IGF receptor mediates both skeletal muscle regeneration after damage and hypertrophy in response to loading.[6] That is established muscle biology. Growth hormone and IGF-1 operate as a linked axis, and growth hormone has sat on the prohibited substances list since the World Anti-Doping Agency was formed.[7] Sporting authorities did not ban it for nothing.
So the reasoning runs: IGF-1 receptor signalling builds muscle, Long R3 activates that receptor while evading the binding proteins, therefore Long R3 builds more muscle. Every step sounds right.
The step that gets skipped is the one where somebody measures it in a person.
There is also a reason the binding proteins exist. The actions and bioavailability of the insulin-like growth factors are regulated by a family of six of them, with IGFBP-3 the most abundant in circulation.[8] A molecule engineered to escape that regulation is not simply a more effective version of the hormone. It is the hormone with a control system removed, and the control system was doing something.
Dosing, as published rather than as advertised
Here is where this article has to stop short, and the reason matters more than the gap.
Researching this piece, I looked for a published dosing protocol for IGF-1 LR3 in humans: micrograms per day, injection frequency, cycle length, anything. There is none. Not a trial protocol, not a case series, not a pharmacokinetic study reporting how long it circulates in a person.
Two specific things I went looking for and could not source:
Whether the reduced binding-protein affinity meaningfully extends its half-life in vivo. Widely asserted, mechanistically plausible, and unsupported by any retrievable study on the compound itself.
A hypoglycaemia risk figure for recombinant IGF-1 treatment. IGF-1 has structural and functional overlap with insulin, so blood sugar is the obvious thing to watch, and I could not find a source quantifying it well enough to print.
The numbers circulating on forums did not come from any of this. They came from somewhere else, and nobody citing them can tell you where.
Side effects, and the one nobody mentions
The safety question that should give a physique-focused reader the longest pause has nothing to do with injection sites.
Higher circulating IGF-1 concentrations are associated with increased risk of prostate cancer, premenopausal breast cancer, and colorectal cancer in prospective studies.[9] That is a large body of epidemiology pointing in one direction, and it is pointing at the exact variable a user is deliberately trying to raise.
Now the honest qualification, because it cuts both ways. Those are observational cohorts. Establishing that a risk factor causally affects an outcome requires designs such as Mendelian randomization, which uses genetic variants as instrumental variables; association on its own cannot do it.[10] So this is not proof that raising IGF-1 causes cancer.
It is also not the reassurance it might sound like. The association is consistent across three separate cancers, and the causal question has not been resolved in the direction of safety. Someone injecting an analogue designed to maximise free IGF-1 activity is running an experiment whose most-studied risk signal is unresolved rather than absent.
What a progress photo cannot tell you
Which brings us back to the galleries.
A before-and-after image cannot separate one compound from everything else happening in the same twelve weeks. Not the training block, not the calorie surplus, not the sleep, not the other three compounds in the same protocol, not the lighting and the pump and the timing of the second photo. It is a record that something changed, attributed by the person who wanted the attribution.
That would be a weak form of evidence even for a well-studied drug. For IGF-1 LR3 it is the only form of evidence that exists, and it is being asked to carry the entire claim.
If you want the defensible version of what is known: the receptor pathway is real, the binding-protein biology explaining why this analogue is potent in a dish is real, and the clinical experience of giving IGF-1 to humans covers a rare paediatric growth disorder and a handful of trials in conditions nothing like yours. The gap between that and a transformation photo is not a gap in the research yet to be filled. Nobody is filling it, because nobody is running the study.
Buy the vial if you want. Just do not tell yourself the photos are data.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Probing the folding pathways of long R(3) insulin-like growth factor-I (LR(3)IGF-I) and IGF-I via capture and identification of disulfide intermediates by cyanylation methodology and mass spectrometry.. The Journal of biological chemistry, 1999.
Analysis of the interaction of insulin-like growth factor I (IGF-I) analogs with the IGF-I receptor and IGF-binding proteins.. Hormone research, 1994.
Managing the child with severe primary insulin-like growth factor-1 deficiency (IGFD): IGFD diagnosis and management.. Drugs in R&D, 2014.
Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation - first three years of Polish experience.. Endokrynologia Polska, 2019.
Randomised al.Phase 2b trial of rhIGF-1/rhIGFBP-3 (OHB-607) for bronchopulmonary dysplasia prevention in preterm neonates: study protocol.. BMJ paediatrics open, 2026.
Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy.. Journal of musculoskeletal & neuronal interactions, 2007.
Growth Hormone and Insulin-Like Growth Factor-1.. Frontiers of hormone research, 2016.
Insulin-like growth factor binding proteins in the human circulation: a review.. Hormone research, 1994.
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis.. Lancet (London, England), 2004.
Meta-analysis and Mendelian randomization: A review.. Research synthesis methods, 2019.
